Home/Pipeline/RenalPro for CA-AKI

RenalPro for CA-AKI

Prevention of Contrast-Associated Acute Kidney Injury

Clinical TrialsActive

Key Facts

Indication
Prevention of Contrast-Associated Acute Kidney Injury
Phase
Clinical Trials
Status
Active
Company

About RenalGuard Solutions

RenalGuard Solutions has developed RenalPro, an automated fluid management system designed to prevent Acute Kidney Injury (AKI). The technology, which has received FDA Breakthrough Device designation, demonstrated a 52% reduction in AKI following cardiac surgery in a randomized controlled trial. The company is positioned to address a major hospital-acquired harm, with CMS set to mandate AKI reporting starting in 2025, creating a significant market driver for preventative solutions.

View full company profile

Therapeutic Areas